Long acting GLP-1 receptor agonist (injectable)
Liraglutide 3.0 mg subcutaneous once daily
LIRA_SC_3p0MG_QD
Related
- All doses pooled: Liraglutide injection
- Liraglutide 1.8 mg subcutaneous once daily
- Liraglutide flexible dose injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.9 mg injection once daily
- Liraglutide flexible dose injection once daily
- Liraglutide 1.2 mg subcutaneous once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg subcutaneous once daily
- Liraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerability
- Liraglutide 2.4 mg injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg injection
- Liraglutide 1.2 mg injection
- Liraglutide 1.25UG/KG injection once daily
- Liraglutide 5.0UG/KG injection once daily
- Liraglutide 7.5UG/KG injection once daily
- Liraglutide 10UG/KG injection once daily
- Liraglutide 12.5UG/KG injection once daily
- Liraglutide 0.3 mg injection once daily
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.35 (0.13 to 13.93) | 0.29 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -3.99 (-7.79 to -0.36) | 0.94 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -3.96 (-15.35 to 8.32) | 0.68 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -5.02 (-11.56 to 2.22) | 0.57 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 4.49 (1.38 to 11.70) | 0.67 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.50 (-1.46 to 2.48) | 0.40 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.98 (0.65 to 1.49) | 0.49 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.69 (1.38 to 5.64) | 0.33 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.07 (2.11 to 4.50) | 0.45 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.44 (2.12 to 5.63) | 0.42 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.15 (1.51 to 3.02) | 0.36 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.41 (1.56 to 3.75) | 0.34 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.41 (0.03 to 4.36) | 0.63 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -0.69 (-11.18 to 10.27) | 0.29 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD -4.26 (-6.86 to -2.07) | 0.51 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -4.45 (-12.56 to 2.75) | 0.56 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -5.85 (-12.32 to 1.01) | 0.50 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -5.44 (-6.89 to -4.01) | 0.30 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -5.11 (-9.87 to -0.40) | 0.32 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -5.36 (-11.24 to 2.01) | 0.37 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 104 to 182 (target week 104) | Placebo | OR 0.36 (0.12 to 1.30) | 0.03 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 3.65 (0.80 to 12.36) | 0.26 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.16 (0.81 to 5.62) | 0.23 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 104 to 182 (target week 104) | Placebo | OR 6.31 (1.45 to 24.78) | 0.64 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 13.05 (2.47 to 55.36) | 0.65 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 1.52 (0.62 to 3.75) | 0.17 |
| Overweight or obesity without diabetes (adults) | Weight loss of 20 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 1.68 (0.54 to 4.83) | 0.17 |
| Overweight or obesity without diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 1.88 (0.46 to 4.11) | 0.62 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.24 (0.85 to 1.79) | 0.47 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 3.39 (1.08 to 13.07) | 0.34 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.91 (3.22 to 4.79) | 0.44 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.86 (2.75 to 5.47) | 0.55 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.59 (1.19 to 2.12) | 0.60 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.61 (1.93 to 3.59) | 0.40 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 10.28 (0.97 to 249) | 0.19 |
| Overweight or obesity without diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 1.91 (0.10 to 38.42) | 0.45 |
| Children and adolescents with obesity | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -3.81 (-8.47 to 2.39) | 0.92 |
| Children and adolescents with obesity | BMI standard deviation score change | weeks 40 to 104 (target week 68) | Placebo | MD -0.22 (-0.55 to 0.13) | 0.47 |
| Children and adolescents with obesity | Percent BMI change | weeks 40 to 104 (target week 68) | Placebo | MD -4.57 (-12.35 to 4.81) | 0.66 |
| Children and adolescents with obesity | Serious adverse events | longest follow-up | Placebo | HR 0.77 (0.16 to 3.71) | 0.63 |
| Children and adolescents with obesity | Nausea | longest follow-up | Placebo | HR 3.54 (1.15 to 10.23) | 0.31 |
| Children and adolescents with obesity | Vomiting | longest follow-up | Placebo | HR 9.95 (2.73 to 38.33) | 0.23 |
| Children and adolescents with obesity | Diarrhea | longest follow-up | Placebo | HR 1.62 (0.46 to 5.70) | 0.42 |
| Children and adolescents with obesity | Constipation | longest follow-up | Placebo | HR 4.95 (0.35 to 154) | 0.23 |
| Polycystic ovary syndrome | Nausea | longest follow-up | Placebo | HR 2.54 (0.73 to 9.53) | 0.27 |
| Polycystic ovary syndrome | Diarrhea | longest follow-up | Placebo | HR 2.94 (0.44 to 24.24) | 0.29 |
| Polycystic ovary syndrome | Constipation | longest follow-up | Placebo | HR 1.42 (0.16 to 16.55) | 0.67 |
Trials
- NCT04311411Effect of Tirzepatide on Energy Intake and Appetite-and Reward-Related Brain Areas in Overweight/Obese Subjects: A Placebo-Controlled 6-Week Study With Functional MRI2020 · 114 randomized · 6 weeks
- S0030172019 · 48 randomized · 52.14 weeks
- STEP 8Effect and Safety of Subcutaneous Semaglutide 2.4 mg Once Weekly Compared to Liraglutide 3.0 mg Once Daily on Weight Management in Subjects With Overweight or Obesity2019 · 338 randomized · 68 weeks
- NCT03856047Investigation of Safety and Efficacy of NNC0174-0833 for Weight Management - a Dose Finding Trial.2019 · 706 randomized · 26 weeks
- SAXAPCOSA Randomized Placebo-controlled Double Blind Trial of Liraglutide 3 mg [Saxenda] on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With Polycystic Ovary Syndrome (PCOS)2018 · 82 randomized · 32 weeks
- BARIOPTIMISEBARI-OPTIMISE: a Double-blinded, Randomised, Placebo-controlled Trial of Liraglutide 3.0 mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response Following Bariatric Surgery2018 · 70 randomized · 24 weeks
- NCT03041792A 6-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO-ARM, PARALLEL METHODOLOGY STUDY TO ASSESS THE EFFECT OF LIRAGLUTIDE ON FOOD INTAKE IN OBESE SUBJECTS2017 · 61 randomized · 6 weeks
- NCT03523273Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity2017 · 136 randomized · 16 weeks
- STRIVEEFFECTIVENESS AND COST OF INTEGRATING A PROTOCOL WITH USE OF LIRAGLUTIDE 3.0 MG INTO AN OBESITY SERVICE: (STRIVE Study)2017 · 392 randomized · 104 weeks
- NCT03038620Impact of Liraglutide 3.0 on Body Fat Distribution, Visceral Adiposity, and Cardiometabolic Risk Markers In Overweight and Obese Adults at High Risk for Cardiovascular Disease2017 · 40 weeks
- SCALE™ InsulinEffect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin2017 · 396 randomized · 56 weeks
- NCT02717858A Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects2016 · 52 randomized · 12 weeks
- S-LITESynergy Effect of the Appetite Hormone GLP-1 (LiragluTide) and Exercise on Maintenance of Weight Loss and Health After a Low Calorie Diet - the S-LiTE Randomized Trial2016 · 195 randomized · 52 weeks
- NCT02918279Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity. 56-week, Double-blind, Randomised, Parallel-group, Placebo-controlled Multi-national Trial Followed by a 26-week Period Off Study-drug2016 · 251 randomized · 56 weeks
- NCT02909933Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity2015 · 30 randomized · 12 weeks
- NCT02527200Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome.2015 · 56 randomized · 52 weeks
- NCT02647944Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity2015 · 40 randomized · 16 weeks
- NCT02453711Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus2015 · 957 randomized · 52 weeks
- NCT01557166Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial2012 · 359 randomized · 32 weeks
- NCT01272219Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation2011 · 3,731 randomized · 56 weeks
- NCT01272232Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: A 56 Week Randomised, Double-blind, Placebo-controlled, Three Armed Parallel Group, Multi-centre, Multinational Trial With a 12 Week Observational Follow-up Period2011 · 846 randomized · 56 weeks
- NCT00781937Effect of Liraglutide on Long-term Weight Maintenance and Additional Weight Loss Induced by a 4 to 12 Week Low Calorie Diet in Obese Subjects; A 56 Week Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Trial With a 12 Week Follow-up Period2008 · 422 randomized · 56 weeks
- NCT00422058Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period2007 · 564 randomized · 52 weeks
- S0030672007 · 564 randomized · 52 weeks